Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

NCT06635954 is registered in ClinicalTrials.gov with Oxford Biodynamics Inc. as lead sponsor.

NCT NCT06635954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06635954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
Lead sponsor
Oxford Biodynamics Inc.
Phase
Observational
Overall status
Recruiting
Start date
May 14, 2024
Completion date
May 14, 2027
Enrollment
2,000 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, immune checkpoint therapy, immunotherapy, pd-1, pd-l1